The objective of the present study was to explore the correlation between the BAFF signal and HCMV-TLR activation in RTx recipients complicated by HCMV. Peripheral blood (anticoagulated by EDTA-Na2 ) and urine of 113 RTx recipients were collected; healthy volunteers were controlled. Urine HCMV-DNA was detected by real-time PCR. Recipients were classified into a positive group (>10,000 copies/mL urine) and a negative group (<10,000 copies/mL urine). ELISA results showed that sBAFF, sera anti-HCMV pp65 immunoglobulin (Ig)G antibody, and total IgG all significantly increased in recipients with positive HCMV-DNA (>10,000 copies/mL urine) (P < 0.05) compared with negative recipients (<10,000 copies/mL urine). In the positive group, HCMV-DNA copies and total IgG positively correlated with sBAFF (r = 0.988 and 0.625, respectively) (P < 0.05). Luminex assay results suggested that the incidence of anti-HLA I and II and MICA antibody obviously increased in positive recipients. The expression level of BAFF and BAFF-R increased in positive recipients. A total of 88 particular genes-involved in TLR signaling pathways, NF-κB signaling pathways, and cytokine-cytokine receptor signaling pathways-were detected in real-time PCR chip assay. A total of 46 genes were differentially expressed greater than two-fold, and the expression characteristic of BAFF-R was concordant with FACS results. Our findings are that activation of HCMV would induce or enhance the activation of BAFF code in RTx recipients, which may independently or cooperatively participate in renal allograft injury and decrease the long-term outcome of renal allografts.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/1348-0421.12167 | DOI Listing |
Front Immunol
December 2024
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
RTX was initially used for non-Hodgkin's lymphoma treatment and has been used in the clinical treatment of various autoimmune diseases as well as in antirejection and immune induction therapy for kidney transplant recipients. Following RTX treatment, the time for B cell regeneration varies among patients, but there is no unified recommendation for the frequency of B cell monitoring. This study aimed to investigate the clinical significance of periodic monitoring of peripheral blood B lymphocytes in individualized immunotherapy following rituximab (RTX) treatment in patients with different diseases.
View Article and Find Full Text PDFClin Transl Oncol
September 2024
Department of Hematology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, NO.19 Xiuhua Road, Xiuying District, Haikou, 570311, Hainan Province, China.
Objective: Chronic graft-versus-host disease (cGVHD) is a significant complication following allogenic hematopoietic stem cell transplantation, often necessitating therapeutic interventions such as rituximab (RTX) and cyclosporin A (CsA). This study aims to elucidate the mechanisms by which RTX and CsA jointly address B-cell dysregulation in cGVHD, providing a theoretical foundation and scientific rationale for the treatment and prognostic evaluation of this condition.
Methods: A total of 30 cGVHD mouse models were established by subjecting recipient mice to total body irradiation followed by injection of a mixed suspension of bone marrow cells and splenocytes from donor mice.
Front Transplant
August 2023
Department of Medicine D, University of Münster, Münster, Germany.
The calcineurin inhibitor (CNI) Tacrolimus (Tac) is the most prescribed immunosuppressant drug after solid organ transplantation. After renal transplantation (RTx) approximately 95% of recipients are discharged with a Tac-based immunosuppressive regime. Despite the high immunosuppressive efficacy, its adverse effects, narrow therapeutic window and high intra- and interpatient variability (IPV) in pharmacokinetics require therapeutic drug monitoring (TDM), which makes treatment with Tac a major challenge for physicians.
View Article and Find Full Text PDFAnn Lab Med
November 2024
Department of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea.
Background: Pronase pretreatment can reduce rituximab (RTX) interference by degrading CD20 in B-cell flow cytometry crossmatch (FCXM) testing. However, it may also reduce the assay sensitivity by degrading HLA molecules. We investigated the effects of various pronase concentrations on RTX interference and the analytical sensitivity of B-cell FCXM testing.
View Article and Find Full Text PDFTransplant Proc
June 2024
Laboratory of Immunology and Experimental Transplantation (LITEX) at Medical School of Sao Jose do Rio Preto (FAMERP), São Jose do Rio Preto, SP 15090-000, Brazil; Organ Transplantation Center, Hospital de Base, FUNFARME, Sao Jose do Rio Preto, SP, Brazil. Electronic address:
Background: COVID-19, caused by SARS-CoV-2, was responsible for higher morbidity and mortality in renal transplant recipients (RTx). The objective of the study was to evaluate the impact of COVID-19 infection on RTx in a single center in Brazil.
Methods: A cohort of 135 RTx was evaluated between December 2019 and June 202l, and demographics, clinical, and laboratory profiles were analyzed from deceased donors with COVID-19.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!